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Antiphospholipid syndrome (APS) is an autoimmune disorder characterized by 
vascular thrombosis (venous or arterial) and/or adverse obstetric outcomes 
accompanied by persistent and elevated levels of antiphospholipid (aPL) 
antibodies. According to the 2006 revised international classification criteria, 
the presence of one among anti-beta2 glycoprotein I (aβ2GPI) IgG or IgM, anti-
cardiolipin (aCL) IgG or IgM and the lupus anticoagulant (LA) is indicated for a 
definite diagnosis of APS. However, not infrequently, none of the “criteria” 
antibodies can be demonstrated. Only recently the so-called “seronegative 
APS” was definitely recognized as a distinctive setting, or better re-defined by 
the demonstration of new classes of aPL antibodies, such as the 
autoantibodies directed against prothrombin (aPT and aPS/PT). In the next 
future, these autoantibodies, particularly aPS/PT, could become additional 
serological classification criteria for APS especially to recognized patients 
negative for classical aPL.  The combination of aβ2GPI, aPS/PT and LA 
demonstrates the best diagnostic accuracy for APS and aPS/PT were recently 
recommended as a surrogate of LA when specific inhibitors and/or analytical 
variables may affect its interpretation.  Despite these recommendations, very 
few clinical laboratories include aPS/PT in routine analyzes so far. Moreover, 
no definite recommendations are available to guide the therapeutic approach 
in patients positive only for aPS/PT antibodies. To clarify their role in APS 
diagnosis and treatment, a better comprehension of its pathogenic 
mechanisms is needed. Thus, the principal aim of this thesis is to investigate 
the pathogenic mechanism underlying the thrombotic manifestations 
associated to the presence of aPS/PT.  To address this issue, the biological 
effects sustained in vitro by aPS/PT were compared to those sustained by 
aβ2GpI, the most studied and recognized player in APS, by developing an 
experimental model able to investigate the thrombotic effect of these 
autoantibodies on monocytes and endothelial cells.  Beside this principal 
study, to improve the risk management of APS patients, the plasmatic activity 
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of the PAF-AH (Platelet Activating Factor Acetylhydrolase) was investigated as 
a new potential prognostic biomarker. PAF-AH is a specific marker of vascular 
inflammation dependent to common lipid metabolism markers (i.e. LDL) which 
is involved in the atherosclerotic plaque instability. 
Obtained data on the TF mRNA expression and Nitric Oxide production 
(colorimetric assay), confirmed that aPS/PT and aβ2GpI exert similar pro-
thrombotic effects on monocytes and endothelial cells. On the contrary, the 
different effect of aβ2GpI and aPS/PT on mRNA expression of IL1β and NLRP3, 
and the different impact on PAF-AH activity (colorimetric assay), may suggest 
that these classes of antibodies probably activate different metabolic 
pathways. Moreover, plasmatic PAF-AH activity in patients with positive aPL 
antibodies appeared to be independent to common lipid metabolism markers 
(i.e. LDL). Based on these results, PAF-AH plasmatic activity may represent a 
new prognostic biomarker also in the context of aPL antibodies, to identify 
patients at major risk and favouring more tailored therapeutic interventions. 
Further prospective studies on selected patients are ongoing.  
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2. ANTIPHOSPHOLIPID SYNDROME (APS) 
Antiphospholipid Syndrome (APS) is a systemic autoimmune disease 
characterized by vascular thrombosis (venous or arterial) and/or adverse 
obstetric outcomes, accompanied by persistent and elevated levels of 
antiphospholipid (aPL) antibodies, namely lupus anticoagulant (LA), 
anticardiolipin antibodies (aCL) or anti-β2 glycoprotein I antibodies (aβ2GpI) 
(Harper, 2011; Gomez-Puerta, 2014).  
2.1 HISTORICAL BACKGROUND 
The antiphospholipid antibody story begins in 1906 when Wasserman 
developed a serological test for syphilis (Arachchillage, 2014). The Wasserman 
reagin test was attributed to antibody reactivity against antigens derived from 
Treponema Pallidum, the causative organism of this infection (Hanly, 2003). In 
1941 Pangborn demonstrated that isolated cardiolipin from bovine heart, was 
the antigenic component of reagin test. The use of purified cardiolipin 
together with lecithin and cholesterol formed the basis for more efficient tests 
as the Venereal Disease Research Laboratory (VDRL) microflocculation assay. In 
1952 Moore and Mohr identified two circumstances in which biological false 
positive for syphilis test could occurs: 
 transient positivity during acute viral infection or after vaccination; 
 persistent positivity (>6 months) associated with autoimmune 
disorders like Systemic Lupus Erythematosus (SLE), Rheumatoid 
Arthritis (RA) and Sjogren’s Syndrome (SjS). 
At same time Conley and Hartmann (1951) wrote a case report of two patients 
with SLE, biological false positive for syphilis and with a “peculiar hemorrhagic 
disorder” (prolongation of prothrombin time). This was the initial description 
of “Lupus Anticoagulant” (LA) (Arachchillage, 2014; Hanly, 2003). 
LA is a biological paradox: in vivo causes thrombotic effects, but in vitro there 
is a prolongation of a phospholipid dependent coagulation test that is not due 
to a specific inhibitor of coagulation factor (Watson, 2012). 
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In the 60’s, the association of LA phenomenon with thrombosis, recurrent 
fetal losses and thrombocytopenia was observed (Gomez-Puerta, 2014). 
The development of more sensitive assay for anticardiolipin antibody (such as 
enzyme-linked immunosorbent assay -ELISA-), facilitated clinical and 
epidemiological studies and description of the APS (Hanly, 2003). 
2.2 CLASSIFICATION CRITERIA AND DIAGNOSIS 
The international criteria for the classification of patients with definite APS 
were defined in 1998 (the so-called “Sapporo criteria”) and then revised in 
2004 during the 11° International Congress on aPL in Sydney. APS is diagnosed 
if at least one of clinical criteria and one of laboratory criteria are both present 
(Table 1) (Wilson, 1999; Miyakis,2006). 
However, there are different features associated with APS, but not included in 
the revised criteria (Table 2) (Miyakis,2006). Only recently APS patients so-
called “seronegative APS” (negative for LA, aCL and aβ2GpI) was definitely 
recognized as a distinctive setting, or better re-defined by the demonstration 
of new classes of aPL antibodies, such as the autoantibodies directed against 
prothrombin (aPT and aPS/PT): in the next future these autoantibodies, 
particularly aPS/PT, could become additional serological  classification criteria 




TABLE 1. REVISED CLASSIFICATION CRITERIA FOR THE ANTIPHOSPHOLIPID 
SYNDROME 
CLINICAL CRITERIA * LABORATORY CRITERIA ** 
1. Vascular thrombosis: one or 
more objectively confirmed 
episodes of arterial, venous or 
small vessel thrombosis 
occurring in any tissue or organ  
2. Pregnancy morbidity:  
a. one or more unexplained 
deaths of a morphologically 
normal fetus at or beyond the 
10th week of gestation; or 
b. one or more premature births 
of a morphologically normal 
neonate before the 34th week 
of gestation because of 
eclampsia, pre-eclampsia or 
placental insufficiency; or 
c. three or more unexplained 
consecutive spontaneous 
abortions before the 10th week 
of gestation. 
1. Lupus Anticoagulant, 
detected according the 
guidelines of International 
Society on Thrombosis and 
Hemostasis (ISTH) 
2. Anticardiolipin Antibody of 
IgG and IgM isotype, 
present in medium or high 
titer (greater than 40 GPL o 
MPL, or greater than 99th 
percentile), measured by a 
standardized ELISA 
3. Anti-β2-glycoprotein-1 
Antibody of IgG and IgM 
isotype, present in titer 
greater than 99th percentile, 
measured by a standardized 
ELISA   
*one or more; ** one or more, present on 2 or more occasions at least 12 weeks apart 




TABLE 2. FEATURES ASSOCIATED WITH APS, BUT NOT INCLUDED IN THE 
REVISED CRITERIA 
CLINICAL CRITERIA  
1. Heart valve disease; 
2. Livedo reticularis; 
3. Thrombocytopenia 
4. Nephropathy; 
5. Neurological manifestation. 
LABORATORY CRITERIA  











The APS could present itself either in a primary form (PAPS), where patients 
have no evidence of other disease; or in a secondary form (SAPS), thus 
associated with another autoimmune disorder among which systemic lupus 
erythematosus (SLE) and rheumatoid arthritis (RA) are the most frequent 
(Gomez-Puerta, 2014).  
In APS, the most frequent site of venous thrombosis is lower limb venous 
system, frequently associated with pulmonary embolism (PE), while cerebral 
vessels are most commonly involved in arterial thrombosis (Watson,2012). 
Different from PAPS and SAPS is the catastrophic APS (CAPS), this is the most 
severe form of APS and is characterized by multiple organ failure usually 
associated with microthrombosis (Aguiar, 2013). 
Prevalence of aPL in the general population ranges between 1 and 5%. 
However, only a minority of these individuals develop the APS (Gomez-Puerta, 




Haemostasis is a tightly regulated homeostatic mechanism that ensures the 
maintenance of blood flow under physiological conditions, but also permits 
rapid, localized coagulation in the event of tissue damage (Allford, 2007; 
Norris, 2003; Panteleev, 2015). A delicate balance exists between four major 
components: vascular endothelium, platelets, the coagulation pathway and 
fibrinolysis (Allford, 2007). 
The traditional concept of coagulation was based on two main pathways that 
were mutually exclusive and of equal importance: the intrinsic (or contact) 
pathway and the extrinsic (or tissue factor) pathway (Allford, 2007; Norris, 
2003). This model (figure 1) described the coagulation as a “cascade” of 
reactions involving activation of several clotting factors resulting in the 
production of a large amount of thrombin and subsequent formation of a 
fibrin clot (Hoffman,2003). However, this cascade paradigm was useful in vitro 
for diagnostic purposes, but failed to explain in vivo phenomena (Allford, 
2007). In 90’s Mann proposed a cell-based model of haemostasis in which was 
emphasized the interaction of clotting factors with specific surfaces, explaining 





Figure 1: The Coagulation “Cascade” (Norris, 2003). 
2.3.1 CELL-BASED MODEL OF HAEMOSTASIS 
The cell-based model has three phases: initiation, amplification and 
propagation phase. 
The initiation phase starts when TF (also called thromboplastin or FIII), comes 
in contact with circulating factor VII activated (VIIa), this complex allows the 
generation of small amount of thrombin (McMichael, 2012). TF is an integral 
membrane protein synthesized and expressed by different types of cells, 
including stromal fibroblasts, mononuclear cells, macrophages and endothelial 
cells (Hoffman, 2003). The majority of TF is not present within the 
bloodstream, only a small amount can be detected in plasma (McMichael, 
2012). 
Haemostasis begins with the formation of the complex between VIIa and TF 
that activates factor IX (IXa) and factor X (Xa). In this way, in vivo, the intrinsic 
and extrinsic pathways are integrated (figure 2). Once assembled, VIIa-TF 
complex activates limited amounts of membrane-bound IX and X. The initial Xa 
produced by this mechanism generates sufficient thrombin to induce local 
platelet aggregation and activation of the critical cofactors V and VIII 
9 
 
(amplification phase). However, it is insufficient to sustain haemostasis 
because of rapid Xa-dependent inactivation of the complex VIIa-TF by TF 
pathway inhibitor (TFPI). Instead, during propagation phase a marked 
expansion is achieved via the action of IXa and VIIIa.  XIa may be required to 
produce additional IXa if insufficient quantities are generated by the VIIa-TF 
complex or fibrinolysis is particularly active. The prothrombinase complex (Xa–
Va-calcium-phospholipids) rapidly converts prothrombin (FII) to thrombin. 
Thrombin hydrolyses the arginine–glycine bonds of fibrinogen to form fibrin 
monomers and activates factor XIII (XIIIa), which stabilizes the fibrin clot by 
cross-linkage. It also has a positive feedback role, promoting activation of 
factor XI and the cofactors V and VIII, and thereby ensuring rapid coagulation 
(Hoffman, 2003; Allford, 2007; McMichael, 2012). 
 
Figure 2: Cell-Based Model of Haemostasis (Allford, 2007). 
 In this model, the coagulation starts when tissue factor (TF) comes in contact 
with circulating factor VII activated (VIIa). In this way, the intrinsic and extrinsic 




2.4 ANTIGENIC TARGETS OF ANTIPHOSPHOLIPID 
AUTOANTIBODIES (aPL) 
The term “Antiphospholipid Syndrome” is used to connect the clinical 
manifestations to the presence of aPL (Amengual, 2003). 
Initially it was thought that these autoantibodies were directed against anionic 
phospholipids, but in the last decade, different groups of investigators have 
been demonstrated that aPL are part of a family of autoantibodies against 
phospholipid-binding plasma proteins or phospholipid-protein complexes.  
Several antigenic targets have been identified among which high and low 
molecular weight kininogens, protein C, annexin V and protein S. However, the 
most common and best characterized target for aPL are β2-Glycoprotein I 
(β2GpI) and prothrombin (PT). All these antigenic targets are involved in 
coagulation system, giving an explication of high incidence of thrombotic 
events in patients with APS (Amengual, 2003). 
2.4.1 β2-GLYCOPROTEIN I 
The main antigenic target for aPL is β2GpI, also known as apolipoprotein H. In 
90’s, it has been demonstrated that aCL associated with APS, were not 
directed against cardiolipin alone, in fact they require a cofactor that is a 
plasmatic protein: β2GpI (Amengual, 2003). 
In human, this protein is synthesized by different cells: hepatocytes, 
endothelial, and trophoblast cells. β2GpI circulates in blood at high 
concentration: the mean serum level is about 200 μg/ml (Miyakis,2004; 
Mahler, 2012). β2GpI is a 50-KDa anionic phospholipid- binding glycoprotein 
that belongs to the CCP superfamily (complement control protein).  
The CCP domain functions as a protein-protein interaction module in many 
different proteins.  β2GpI is organized in five CCP domains: the first four 
domains have regular, conserved sequences, while the fifth domain is aberrant 
and has additional amino acids (multiple lysine). This amino acid strain creates 
a positively charged domain that is responsible for the binding to the anionic 
phospholipids. The crystal structure shows that the phospholipid-binding site 
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is located at the bottom side of domain V and predicts that the potential 
binding site for aβ2GpI is located in domain I (Groot, 2011; Miyakis,2004). 
β2GpI can exist in plasma in two different conformations: closed/circular or 
open/hockey-stick like conformations. As shown in figure 3, binding of β2GpI 
to anionic surfaces results in a conformational change: the conversion from 
closed to open conformation leads to expose the antibody-binding site, that is 
not accessible to autoantibodies in the closed conformation (Groot, 2011; 
Harper,2011). 
About its physiological role, not many other information are available, but it is 
supposed that β2GpI plays an important role in biology, since it shares high 
homology with different mammalian species (Miyakis, 2004). The homology 
with other proteins involved in innate immunity suggests that β2GpI could 
play a role in host defense against bacteria (Groot, 2011). 
Multi-centric studies have found a strong association between aβ2GpI 
antibodies and history of thrombosis (Mahler, 2012). Moreover recent studies 
have shown that aβ2GpI antibodies associated with major risk of thrombosis, 
bind the domain I of the β2GpI, that is exposed in the open conformation 
(Harper, 2011), as already demonstrated by Andreoli et. al, who have 
demonstrated that only autoantibodies directed against domain I of β2GpI are 
associated with increased risk of thrombosis, while a significant lower risk of 
thrombosis has been found in case of aβ2GpI antibodies targeting other 




Figure 3: Model of cell activation by autoantibodies against β2GpI (Tripodi, 
2011) 
β2GpI circulates in plasma in a closed conformation. When β2GpI binds anionic 
phospholipids, changes its conformation from a closed to an open structure. In 
this way, the epitope for autoantibodies are exposed. Then β2GpI is able to 
interact with receptor on the surface of the cells. 
2.4.2 PROTHROMBIN 
Prothrombin is another major phospholipid-binding protein recognized by aPL. 
It is a vitamin K-dependent proenzyme synthesized in the liver as inactive 
zymogen that circulates in blood at concentration of 100 μg/ml (Amengual, 
2003). 
Mature human prothrombin is a protein of 579 amino acids with a molecular 
weight of 72-KDa. To exert its procoagulant activity converting fibrinogen to 
fibrin, prothrombin is physiologically activated by the prothrombinase complex 
(Xa-Va-calcium-phospholipids): the vitamin K-dependent carboxylation of the 
γ-carboxyglutamic domain located in fragment 1 of prothrombin allows to 
bind to the negatively charged phospholipids and consequently the activation 
of FII (Amengual, 2003; Sciascia and Khamashta, 2014). 
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2.5 APS AND THROMBOSIS 
A strong association between aPL and thrombosis has been demonstrated, but 
nevertheless the pathogenic role of aPL in the development of thrombosis 
should be clarified (Gomez-Puerta, 2014).  
2.5.1 THE “TWO-HIT” HYPOTHESIS 
In APS, the key elements involved in pathogenic mechanism of thrombosis are: 
 cellular component of vessels; 
 humoral components that regulate haemostasis (coagulation factor, 
natural anticoagulants and fibrinolytic system); 
 inflammation (inflammatory cells, soluble inflammatory mediators and 
infectious agents) (Willis, 2015).  
The complex interaction of these elements, lead to proinflammatory and 
prothrombotic state, for this reason, it is referred to as the “two-hit” 
hypothesis. Theory postulates that even though the persistence of elevated 
levels of aPL is a necessary condition, the occurrence of APS is seemingly 
triggered by an additional “second hit”, such as trauma or infection (Willis, 
2015; Brandt, 2013). 
2.5.1.1 CELLULAR COMPONENTS 
The aPL are directed against anionic phospholipids, therefore several studies 
have investigated the interaction of β2GpI with cellular membranes and cells. 
Both in vitro and in vivo studies have shown that the complex β2GpI-aβ2GpI 
can bind and activate many different cells such as endothelial cells (ECs), 
monocytes and platelets (Tripodi, 2011). 
Activation of endothelial cells by aPL is a major thrombogenic mechanism. The 
specific binding of aβ2GpI to EC up-regulates the cell-surface expression of cell 
adhesion molecules (CAMs): intracellular adhesion molecule-1 (ICAM-1), 
vascular cell adhesion molecule-1 (VCAM-1) and E-selectin, promoting 
leukocyte adhesion (Willis, 2015; Brandt, 2013). 
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Furthermore, activated EC up-regulate the expression of TF (the key initiator of 
the coagulation pathway), microparticle formation,  fibrinolysis inhibitor PAI-1 
and inflammatory cytokines/chemokines such as IL-6, monocyte chemotactic 
protein-1 (MCP-1), fractalkine (Meroni, 2001). On the other side activation of 
endothelium leads to decrease expression of thrombomodulin (Meroni, 2001; 
Rikarni, 2015). These finding suggest that the complex β2GpI-aβ2GpI can 
induce an endothelial activation either directly or by cytokine autocrine loop 
(Meroni, 2001). Another mechanism involved in thrombus formation is 
vasoconstriction: endothelium regulates vessel tone through endothelin-1 
peptide, the most potent endothelium-derived contracting factor (Meroni, 
2001); supporting this idea, Atsumi et al, reported that plasma level of 
endothelin-1 peptide significantly correlated with history of thrombosis in APS 
patient (Atsumi, 1998). All these mechanisms lead to a 
procoagulant/proinflammatory phenotype that increases the risk of 
thrombotic occlusions (Brandt, 2013).  
The monocytes are another player in the development of thrombosis in APS 
patients, indeed exposed to aPL, monocytes up-regulate expression of TF via 
p38 MAPK pathway, resulting in nuclear factor-kB (NF-kB) activation (Willis, 
2015; Brandt, 2013). TF expression is associated with increased plasma levels 
of vascular endothelial growth factor (VEGF) and cell surface expression of 
both VEGF and the Flt-1 tyrosine kinase receptor. Stimulation of Flt-1 tyrosine 
kinase receptor by VEGF results in TF mRNA and protein expression. 
Furthermore, monocytes derived from APS patients or normal monocytes 
exposed to aPL, show an increased expression of protease-activated receptor 1 
(PAR-1) and PAR-2. This is very significant because that PAR-1 and PAR-2 
mediate several effects of thrombin such as up-regulation of proinflammatory 
cytokines (IL-6, IL-8, MCP-1) (Harper, 2011; Willis, 2015).  
In vivo, platelets are central to arterial thrombus formation, indeed in APS 
patients, platelet activation is increased. Plentiful evidence from 
epidemiological and mechanistic studies indicates that aPL activate platelets, 
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resulting in increased expression of thromboxane B2 (TXB2), fibrinogen 
receptor glycoprotein IIb/IIIa (GPIIb/IIIa) and consequently platelet 
aggregation (Harper, 2011; Willis, 2015). Urbanus et al. demonstrated that 
plasma β2GpI does not bind to platelets, whereas β2GpI in complex with 
aβ2GpI does bind to platelets (Urbanus, 2008). The platelet receptors involved 
in the interaction of β2GpI/aβ2GpI complex are apolipoprotein E receptor 2 
(ApoER2) and von Willebrand factor receptor glycoprotein Ibα (GPIbα) 
(Harper, 2011; Urbanus, 2008). Therefore β2GpI/aβ2GpI complex can bind to 
ApoER2 and/or GPIbα and this binding mediates the activation of platelets and 
the induction of thromboxane A2 synthesis (Urbanus, 2008). 
Finally, activated platelets secrete platelet factor 4 (PF4), a member of the CXC 
chemokine family with multiple prothrombotic effects (inhibition of 
inactivation of thrombin by antithrombin, potentiation of platelet aggregation 
and accelerating cleavage of activated protein C) and also and antigenic target 
in APS (Harper, 2011; Giannakopoulos, 2013). 
The activation of all these cell types by aPL coupled with the release of several 
proinflammatory mediators has linked to the development of thrombosis in 
APS animal models and in same case in human APS patients (Willis, 2015). 
2.5.1.2 HUMORAL FACTORS 
aPL act at various levels of the coagulation cascade leading to uncontrolled 
fibrin formation and impaired thrombus resolution (Willis, 2015). 
Direct activation of prothrombin binding to the surface of ECs, has been 
demonstrated in APS patients and has been attributed to anti-prothrombin 
antibodies (aPT) with LA activity; this activation induces TF expression and 
thrombosis (Willis, 2015; Amengual, 2003). Furthermore, aPL bind directly to 
antithrombin III (ATIII) resulting in reduced inactivation of FIXa and FXa (Willis, 
2015; Harper, 2011).  
aPL interfere with the fibrinolytic system: the action of β2GpI/aβ2GpI complex 
on endothelium leads to decrease thrombomodulin expression (TM) and tp 
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increase of plasminogen activator inhibitor (PAI-1), this might be one of the 
causes of thrombophilic diathesis in APS (Meroni, 2001; Rikarni ,2015). 
Modulation of activated protein C (APC), a phospholipid-dependent major 
antithrombotic pathway, has been found in APS patients who have increased 
resistance to APC resulting in greater thrombin generation overtime (Meroni, 
2001; Harper, 2011; Willis, 2015). 
Finally, it has been hypothesized an involvement of annexin 5 (A5): normally 
A5 binds to phosphatidylserine surfaces of ECs, forming a shield that inhibits 
the formation of procoagulant complex; in a model of the pathogenesis of the 
antiphospholipid syndrome, aβ2GpI that bind to the domain 1 of the β2GpI 
can disrupt the A5 antithrombotic shield present on the endothelial cells 
(Giannakopoulos, 2013; Tripodi, 2015). 
Overall, the resistance of activated coagulation factors to inactivation and the 
reduced activity of natural anticoagulant and fibrinolytic agents, potentiate 
unchecked fibrin formation and the thrombogenic state (Willis, 2015; Tripodi, 
2011). 
2.5.1.3 INFLAMMATION 
In addition to activation of the coagulation pathway, APS is characterized by 
proinflammatory changes. Indeed, inflammation acts as a key trigger event for 
the thrombotic manifestation of APS and it is very important for changes in 
antigen conformation and immune cell activity, critical elements in aPL 
ontogeny (Harper, 2011; Willis, 2015). 
Several studies have demonstrated that APS patients are characterized by 
increased oxidative stress:  paraoxonase activity (a glycoprotein that prevents 
oxidation of low-density lipoprotein-LDL- cholesterol) is significantly decreased 
in these patients, whereas 8-epi-prostaglandin F2∝, a biomarker of lipid 
peroxidation, is upregulated (Giannakopoulos, 2013). 
In APS patients, oxidative stress has an effect on β2GpI, in fact APS patients 
frequently show high levels of oxidized β2GpI. Oxidative stress acts on β2GpI 
at different levels: 
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 increases β2GpI production through gene promoter up-regulation via 
nuclear factor kappa B (NFkB);  
 increases the immunogenicity of β2GpI through post-translational 
modification; 
 induces conformational changes exposing hidden epitopes of β2GpI, 
important for aPL production (Willis, 2015) 
It has been proposed that disturbance of redox balance in patients with APS 
could constitute the “first hit” which allows the formation of β2GpI/aβ2GpI 
complex on ECs (Giannakopoulos, 2013). 
Furthermore, oxidative stress can up-regulate annexin II (A2) expression, an 
endothelial receptor that mediates the binding of β2GpI to ECs (Ma, 2000), 
and, in a murine model of thrombosis, induces platelet aggregation, EC 
stimulation and von Willebrand factor expression (Nishimura, 2011). 
Patients with APS have decreased levels of plasma nitrite, as compared with 
controls. This suggests an abnormal activity of endothelial nitric oxide 
synthase (e-NOS). Endothelium-derived nitric oxide is fundamental for normal 
function of endothelium and a reduced expression of e-NOS results in 
superoxide and peroxynitrite production (Giannakopoulos, 2013). 
Activation of the complement cascade also contributes to the pathogenic 
effects of aPL; in particular, the anaphylatoxins C3a and C5a induce the 
inflammatory vascular phenotype of APS and are necessary players connecting 
EC, monocytes, and platelet activation by aPL and the thrombotic 
manifestation (Willis, 2015). 
2.6 APS AND PREGNANCY 
The risk for adverse pregnancy outcomes, such as recurrent miscarriage, fetal 
demise, placental insufficiency, preeclampsia and intrauterine growth 
restriction (IUGR) in women with APS is greatest from the 10th week of 
gestation onward (Hanly,2003; Mulla, 2013). 
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There is also evidence that these women have an increased risk of giving birth 
to a premature infant because of pregnancy-associated hypertension and 
utero-placental insufficiency (Hanly, 2003). 
Unlike the systemic APS that is a prothrombotic and proinlammatory disease, 
obstetric APS (OAPS) is primarily a proinflammatory syndrome (Mulla, 2013). 
Indeed, the first hypothesis that OAPS was due to an intraplacental thrombosis 
with consequently alteration of maternal-fetal blood exchanges, has not been 
confirmed by histological studies (Khamashta, 2016). 
Different groups of investigators have been postulated two mechanisms for 
aPL-induced pregnancy morbidity: defective placentation and inflammation 
(Khamashta, 2016). 
In the placenta, aβ2GpI can react with both sides, maternal and fetal (Simone, 
2000). This ability induces direct placental damage with different mechanisms: 
  inhibiting trophoblast differentiation and syncytialization; 
  inducing trophoblast apoptosis; 
  impairing trophoblast invasiveness; 
 affecting trophoblast expression of adhesion molecules that regulate 
its adhesion to and invasion of the maternal tissue; 
 inhibiting production of angiogenic factor by trophoblasts (Khamashta, 
2016; Tong, 2014). 
Moreover, has been proposed as an additional mechanism for preeclampsia 
due to the internalization of aPL by trophoblasts with the subsequent 
acceleration of cell death and release of debris that can activate maternal 
endothelial cells (Khamashta, 2016). 
It has been proved that inflammation has an important role in OAPS. This idea 
is based on: 
 the histological demonstration of complement deposition, neutrophil 




  the observation that complement deficiency in animal models or 
complement inhibition in vivo are protective against obstetrical 
complications; 
 the evidence of a protective effect of heparin linked to its anti-
complement activity; 
 the observation in in vitro studies that aPL can induce 
trophoblasts to produce interleukin-1 β (IL1β) by activation of 
inflammasome (Mulla, 2013; Khamashta, 2016; Müller-Calleja, 2015). 
2.6.1 aPL AND INFLAMMASOMES 
Inflammasomes (NLR) are large soluble cytoplasmatic complexes that are 
capable of activating the cystein protease caspase-1 in response to a wide 
range of stimuli including microbial and self-molecules. The activation of 
inflammasome leading to the processing and activation of pro-IL1β and pro-
IL18 through caspase-1 (Chen, 2009). Inflammasome includes several 
members: NLRP1, NLRP3, NLRP6, NLRP7, NLRP12, NLRC4 and NAIP proteins 
(Barbè, 2014).  The most well characterized are NLRP1 and NLRP3 (figure 4) 
and different studies on OAPS, have associated the production of IL1β with the 




Figure 4: Mechanism of Inflammasome.  
Three different Inflammasome (NLRC4, NLRP3 and NLRP1) activate caspase-1 
in response to several stimuli such as microbial component or crystal; in this 
way, pro-IL1β and pro-IL18 are processed 
2.7 RISK FACTORS OTHER THAN aPL IN APS PATIENTS 
Recently, the role of vascular risk factors in the development of clinical events 
in patients with APS has been established (Khamashta, 2016).  The presence of 
multiple risk factors such as hypertension, smoking, hypercholesterolemia, or 
estrogen use may increase the occurrence of thrombosis in patients with aPL 
(Erkan, 2002). 
SLE is a risk factor for thrombosis per se: in patients with SLE there are a 
higher-than-expected incidence of vascular events, which are not completely 
explained by traditional vascular risk factors (Esdaile, 2001). The combination 
of SLE and aPL positivity has been shown to increase the risk of thrombosis. 
Indeed, in SLE patients with aPL positivity, the annual risk of first thrombosis is 
higher than in healthy aPL positive subjects without other cardiovascular risk 
(4% vs < 1%) (Khamashta, 2016). 
21 
 
Thrombotic risk assessment should be considered also in patients with 
primary APS, such as women with a history of pregnancy morbidity due to 
aPLs (OAPS). In fact, these patients have a higher thrombotic event rate than 
healthy women (3.3 vs 0-0.5/100patients-years) (Lefevre, 2011). 
Moreover, there are many aPL carriers that never develop APS, only few cases 
will develop thrombosis or obstetrical manifestations and only a very small 
group will develop CAPS. In this scenario, it could be of great advantage to 
make a risk stratification of thrombotic/obstetric events in such patients. 
To date, three score model have been proposed for risk stratification: the first 
two scores are focused on the aPL profile, while the third, the Global APS 
Score (GAPSS) included other variables such as autoimmune profile or 
cardiovascular risk factor. This model seems to be the better one (Khamashta, 
2016).   
To help clinicians in patient management, in addition to GAPSS, it would be 
useful to identify a new specific plasmatic biomarker, independent from the 
other classic risk factors for thrombosis. 
2.7.1 PLASMATIC PLATELET-ACTIVATING FACTOR 
ACETYLHYDROLASE ACTIVITY (PAF-AH) 
Platelet activating factor acetylhydrolase activity (PAF-AH) is a Ca2+-
independent A2 phospholipase, also known as lipoprotein-associated 
phospholipase A2 (Lp-PLA2). The plasmatic PAF-AH is constitutively active and 
circulates bound to LDL, HDL and other lipoproteins. PAF-AH hydrolyzes the 
ester bond at the sn-2 position of phospholipids, such as PAF and PAF 
mimetics, that are early mediators of inflammation (McIntyre, 2008). PAF 
activates a variety of cells of the innate immune system promoting migration, 
adhesion and inflammatory effects. Thus, PAF-AH while inactivating PAF, is 
considered an important factor to prevent an exaggerated inflammatory 
response and to protect cells from uncontrolled oxidative damage (Rosenson, 
2012). Several studies have shown an association between high levels of PAF-
AH activity and the severity of cardiovascular diseases and identified PAF-AH 
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as a marker of vascular inflammation involved in the atherosclerotic plaque 
instability (Davidson, 2008; Maiolino, 2012). To date, there are not study on 
PAF-AH activity and APS. 
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3. AIM OF THE STUDY 
Numbers of recent papers underlined the important role of aPS/PT. In 
particular, the combination of aβ2GPI, aPS/PT and LA demonstrates the best 
diagnostic accuracy for APS and aPS/PT were recently recommended as a 
surrogate of LA when specific inhibitors and/or analytical variables may affect 
its interpretation (Bertolaccini, 2011). Despite these recommendations, very 
few clinical laboratories include aPS/PT in routine analyses so far. Moreover, 
no definite recommendations are available to guide the therapeutic approach 
in patients positive only for aPS/PT antibodies. To clarify their role in APS 
diagnosis and treatment, a better comprehension of its pathogenic 
mechanisms is needed. Thus, the principal aim of this thesis is to investigate 
the pathogenic mechanism underlying the thrombotic manifestations 
associated to the presence of anti-phosphatidylserine-prothrombin 
antibodies.  To address this issue, since aβ2GpI antibodies represent the most 
studied and recognized player in APS, I decided to compare the biological 
effects sustained in vitro by aPS/PT to those sustained by aβ2GpI, by 
developing an experimental model able to investigate the thrombotic effect.  
Beside this principal study, to better assess the atherosclerotic risk in APS 
population and improve the risk management of these patients in the follow-
up, I will investigate a new potential prognostic biomarker, such as the 
plasmatic activity of the PAF-AH (Platelet Activating Factor 
Acetylhydrolase), that is a specific marker of vascular inflammation involved in 
the atherosclerotic plaque instability. 
4. MATERIAL AND METHODS 
4.1 PATIENTS 
For in vitro experiments, total IgG were purified from six selected patients, in 
particular three positive only for aβ2GpI IgG and three positive only for aPS/PT 
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IgG, all were LA positive. Patients positive for aβ2GpI IgG all recognized also 
the domain I. As controls, total IgG were purified from five blood donors (BD), 
who were tested negative for LA, aβ2GpI and aPS/PT antibodies. 
The plasmatic PAF-AH activity was evaluated in a series of 167 consecutive 
unselected patients (124 females and 69 males; mean age: 51±16 years) 
screened for the presence of aPL at the Laboratory of Immunopathology of the 
University Hospital of Udine in a routinely context of thrombotic events, risk of 
thrombosis or obstetric complications. Patients were compared to 77 blood 
donors (BDs; 39 females and 38 males; mean age: 39±13 years) enrolled at the 
Transfusion Unit of the same Hospital. 
All patients and controls gave their informed consent to these studies 
according to the Declaration of Helsinki and to the Italian legislation 
(Authorization of the Privacy Guarantor No. 9, 12 December 2013). 
4.2 ANTIBODY DETERMINATION AND ANTIGENIC 
SPECIFICITY 
4.2.1 LA 
Plasma samples were tested for the presence of LA at the Laboratory of 
Haemostasis of the University Hospital of Udine, according to the 
recommended criteria from the ISTH Subcommittee on Lupus Anticoagulant-
Phospholipid-dependent antibodies. 





Figure 5: Flowchart for the Laboratory Detection of Lupus Anticoagulants 
(Tripodi, 2011).  
* the presence of heparin is ruled out by a normal thrombin clotting time; § 
PNP, pooled normal plasma; PL, phospholipids. 
4.2.2 aCL and aβ2GpI 
Anti-cardiolipin (aCL) IgG/IgM and anti-β2GpI (aβ2GpI) IgG/IgM antibodies 
(figure 6) were detected by commercial methods (CLIA, Zenit RA, Menarini 
Diagnostic; cutoff IgG 10, IgM 20). Anti-β2GpI IgG antibodies specifically 
directed against domain I were detected by CLIA using the Inova Diagnostic Kit 





Figure 6: CLIA System for detection of aCL IgG/IgM and aβ2GpI IgG/IgM 
(Menarini Diagnostic) 
The assay is based on a two-step indirect chemiluminescent method that 
generates quantitative results. This particular technique uses autoantigen-
coated magnetic particles as slid phase and an antibody labeled with dimethyl 
acridinium ester (DMAE) as detection marker. 
4.2.3 aPS/PT 
The aPS/PT IgG and IgM antibodies, in serum samples, were analyzed by ELISA 
(figure 7) using the Quanta Lite aPS/PT IgG/IgM ELISA kit (Inova Diagnostic Inc, 
San Diego, CA; cutoff IgG 40 AU/ml, IgM 30 AU/ml).  
 
Figure 7: ELISA System for the detection of aPS/PT (Sciascia and Khamashta, 
2014). Antibodies are able to bind prothrombin (PT) when it is exposed to 
immobilized anionic phospholipids. 
4.3 MEASUREMENT OF PAF-AH ACTIVITY  
The plasmatic PAF-AH activity was assessed by a colorimetric assay (PAF-AH 
Assay Kit- Cayman Chemical Company, Ann Arbor, Michigan, USA). Briefly 
(figure 8) serum samples were incubated with the substrate 2-thio PAF, that is 
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hydrolyzed by PAF-AH at the sn2-position releasing free thiols detected by 
DTNB Ellman's reagent (5,5'-dithio-bis-2-nitrobenzoic acid). 
 
Figure 8: PAF-AH Assay Scheme (Cayman Chemical Company)  
4.4 ISOLATION OF IgG 
Total IgG from patients and controls were purified from serum samples with 
two different methods: 
 affinity chromatography (figure 9);  
 immunopurification with magnetic beads (figure 10). 
For affinity chromatography, it was used Rec.Protein A-Sepharose® 4B 
Conjugate (Life Technologies) according to the manufacturer's instruction. 
Briefly, Rec.Protein A-Sepharose® is a bead-formed agarose-based gel filtration 
matrix where Protein A from Staphylococcus aureus was immobilized. Protein 
A binds to Fc region of immunoglobulins (Igs) through interaction with heavy 
chain. To elute IgG from Protein A-Sepharose®, 0.1 M glycine buffer pH 3.0 was 
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used; to preserve the activity of purified IgG, the pH of fractions was 
neutralized by addition of 1: 10 vol/vol of 1 M Tris-HCl pH 9.0. 
For the immunopurification of IgG with magnetic beads, PureProteomeTM  
Protein A Magnetic Beads (Millipore) was used, according to  the 
manufacturer's instruction. As for affinity chromatography, Fc region of IgG 
binds recombinant Protein A from Staphylococcus aureus covalently coupled 
with polymer-coated inorganic beads. A glycine buffer (0.2 M, pH 2.5) was 
used also to elute the bound IgG; after the elution, the solution with IgG was 
neutralized with Tris-HCl 1 M pH 8.5.  
The purity of immunopurified IgG was verified by immunofixation diagnostic 
assay performed on the fully automated gel electrophoresis instrument 
InterlabG26 (Interlab). 
The immunopurified IgG was quantified by spectrophotometry and checked by 
Sodium Dodecyl Sulfate- Polyacrylamide Gel Electrophoresis (SDS-PAGE).   
High titer of aβ2GpI or aPS/PT were measured in the IgG fraction purified from 
patient sera, while the IgG fraction obtained from BD sera remained negative. 
 
 





Figure 10:  Isolation of IgG Fraction from Serum with Immunobeads 
4.5 CELL CULTURE 
4.5.1 ISOLATION OF MONOCYTES  
Monocytes were isolated from fresh peripheral blood mononuclear cells 
(PBMCs). Briefly, peripheral blood mononuclear cells (PBMCs) were isolated 
from fresh blood of five blood donors by gradient centrifugation (Ficoll-Paque 
Plus). The cells were collect and washed with PBS. Monocytes were isolated 
from PBMCs by negative selection using the Human Monocyte Enrichment Kit 
(Stemcell Technologies) according to the manufacturer's protocol. Isolated 
monocytes were cultured overnight in RPMI-1640 (Sigma-Aldrich) 
supplemented with 0.02 M HEPES (Sigma-Aldrich), 100 μM penicillin-
streptomycin (Sigma-Aldrich), and 10 vol% heat-inactivated Fetal Bovine 
Serum (FBS,Gibco) in humidified atmosphere (5 vol % CO2, 37°C).  
4.5.2 HUVEC 
Human Umbilical vein endothelial cells (HUVECs) (Gibco), were maintained 
under 5 vol% CO2 at 37°C in M199 (Sigma-Aldrich) supplemented with 100 μM 
penicillin-streptomycin (Sigma-Aldrich), and 10 vol% heat-inactivated Fetal 
Bovine Serum (FBS, Gibco). 
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4.6 PROCOAGULANT CELL TREATMENT 
To test prothrombotic effect of the fraction of IgG aPL positive, cells were 
treated as shown in table 3 for 4, 16 and 24 hours (Oku, 2013; Raschi, 2014).  
Monocytes and HUVECs were treated for 4 h for mRNA analysis and for 8, 16 
and 24 h for cytokine and chemokine expression. 
  
TABLE 3. PROCOAGULANT TREATMENT FOR MONOCYTES AND HUVECs 
 UN*
*** 
LPS BD aβ2GpI aPS/PT 
Ca2+ (2.5mM) *  ✓ ✓ ✓ ✓ 
PT **  ✓ ✓ ✓ ✓ 
LPS (1ng/ml) ***  ✓ ✓ ✓ ✓ 
IgG BD (500μg/ml)   ✓   
IgG aβ2GpI (500μg/ml)    ✓  
IgG aPS/PT (500μg/ml)     ✓ 
 
*This concentration of Ca2+ was sufficient to facilitate the binding of PT to 
phosphatidylserine 
**PT (prothrombin) were added to monocytes at a concentration of 10μg/ml 
and to HUVECs at a concentration of 15μg/ml. 
***LPS (lipopolysaccharide) were added to pre-activate cells and to mimic the 
“second-hit” 




4.7 RNA ISOLATION AND REAL-TIME PCR 
Total RNA was extracted from the cells using ReliaPrepTM   RNA Cell Miniprep 
System according to the manufacturer’s protocol and stored at -80°C until use. 
RNA quantification was determined with NanoDrop ND-1000 
Spectrophotometer (NanoDrop Technologies Inc, Wilmington, Del). The purity 
of the RNA samples was evaluated with the optical density 260:280 and 
260:230 ratio and with denaturing agarose gel electrophoresis and ethidium 
bromide staining. 
Complementary DNA (cDNA) was generated using the iScriptTM Select cDNA 
Synthesis Kit (Bio-Rad Laboratories) according to the random primer protocol 
provided by the manufacturer.  
In order to evaluate mRNA relative expression of TF, IL1β, NLRP1 and NLRP3, 
real-time PCR was performed using SsoAdvance universal SYBR green 
supermix (Bio-Rad Laboratories) and a LightCycler 480 (Roche Diagnostics Ltd) 
according to the manufacturer’s instructions. The primers used are shown in 
table 4. The result of mRNA expression was analyzed by measuring threshold 




TABLE 4:  PRIMER SEQUENCES* USED FOR TF, IL1β, NLRP1 AND NLRP3 GENE EXPRESSION 
ANALYSES 
Genes Analysed Forward (sequence 5'-3') Reverse (sequence 5'-3) 
TF TGTTCAAATAAGCACTAAGTCAGGAGAT TCGTCGGTGAGGTCACACTCT 
IL1β TGCCCGTCTTCCTGGGAGGG GGCTGGGGATTGGCCCTGAA 
NLRP1 GACCTGGCCTCTGTGCTTAG AGTCCCCAAAGGCTTCGTAT 
NLRP3 CTGTGTGTGGGACTGGAAGCAC GCAGCTCTGCTGTTTCAGCAC 
GAPDH AGTATGACAACAGCCTCAAG TCTAGACGGCAGGTCAGGTCCAC 
*Primers were projected to target two consecutive exons of gene in order to prevent the 
amplification of any contaminating genomic DNA 
 
4.8 MEASUREMENT OF NITRIC OXIDE (NO) PRODUCTION 
After stimulation of HUVECs for 16 as described previously, supernatants were 
aspirated, centrifuged at 15500 g (5 min, 4°C), and stored at -80°C until 
quantification of NO production. 
The measurement of NO levels was performed using a colorimetric assay 
(NITRATE/NITRITE COLORIMETRIC Assay Kit- Cayman Chemical Company, Ann 
Arbor, Michigan, USA) according to the manufacturer’s instruction. Briefly, NO 
is scavenged rapidly (t1/2), the final products (NOx) in vivo are nitrite (NO2-) and 
nitrate (NO3-), thus the best index of total NO production is the sum of nitrite 
and nitrate.  This assay is a two-step process (figure 11). The first step provides 
a conversion of nitrate to nitrite through the nitrate reductase. Griess Reagent 
is added during second step, converting nitrite in a deep purple azo-
compound. Concentrations were calculated by comparing absorption of 




Figure 11: Griess Reagent Chemistry (Cayman Chemical Company)  
4.9 QUANTIFICATION OF CYTOKINES AND CHEMOKINES 
After stimulation of HUVECs for 16 and 24h as described previously, 
supernatants were aspirated, centrifuged at 15500 g (5 min, 4°C), and stored 
at -80°C until quantification of cytokines and chemokines. For the 
quantification was used Bio-Plex ProTM   Human 2-Plex Panel (ICAM-1 and 
VCAM-1) and Bio-Plex ProTM    Human Chemokine 40-Plex Panel (table 4) with 
Bio-Plex 200 system (Bio-Rad Laboratories). This simultaneous dosage is based 
on Luminex® Technologies (figure 12). Briefly paramagnetic beads are 
internally dyed with red and infrared fluorophores of differing intensities, each 
dyed bead is given a unique number allowing the differentiation of one bead 
from another. In this way, multiple analyte-specific beads can then be 
combined in a single well of a 96-well microplate-format assay to detect and 
quantify different targets simultaneously. 





Figure 12: Bio-Plex sandwich immunoassay 
 
 Table 4 Bio-Plex ProTM    Human Chemokine 40-Plex Panel 
CCL21 CXCL1 IL16 CCL3 
CXCL13 CXCL2 CXCL10 CCL15 
CCL27 CCL1 CXCL11 CCL20 
CXCL5 IFNϒ CCL2 CCL19 
CCL11 IL1β CCL8 CCL23 
CCL24 IL2 CCL7 CXCL16 
CCL26 IL4 CCL13 CXCL12 
CX3CL1 IL6 CCL22 CCL17 
CXCL6 IL8 MIF CCL25 
GM-CSF IL10 CXCL9 TNFα 
4.10 STATISTICAL ANALYSIS  
Quantitative variables were expressed as mean ± standard deviation (SD) and 
checked for normality distribution by the Shapiro Wilk test. To compare 
biomarker serum levels between patient and control series, either Mann-
Whitney or unpaired t-test was used when appropriate. Correlation analysis 
were performed using the Pearson's or the Spearman's rank correlation 
coefficient, when appropriate. Statistical analyses were performed with 





5.1 IgG PURIFICATION 
The IgG fractions were obtained with both methods, affinity chromatography 
and immunopurification with magnetic beads. The purification was checked 
with two different techniques: SDS-page and immunofixation. 
As shown in figure 13, to identify the fraction of interest, the different eluates 
were verified by SDS-page. The absence of contamination by other 
immunoglobulins, was verified by immunofixation technique (figure 14). 
A highly-purified IgG fractions, were obtained both by affinity chromatography 
and immunopurification. The only difference between these two methods, 
was the quantity of input material versus the final yield: immunopurification 
starts from a small amount of serum while in affinity chromatography, the 
quantity of input material is proportional to the volume of Sepharose®. In 
order to obtain sufficient IgG for procoagulant treatment, the affinity 
chromatography was finally chosen. 
 
Figure 13: Purification of IgG from Human Serum with affinity chromatography 
(lanes 1-5) and immunoprecipitation (lanes 6-7) 
Lines 1 and 6 show the input material, lane 2 shows serum depleted from IgG, 
lanes 3-5 and 7 show the bound IgG fraction, lane 8 shows bovine serum 




Figure 14:  Immunofixation of the input material (A), serum depleted of IgG (B) 
and IgG fraction. 
 As shown in panel B, in serum depleted, IgG are absent and (panel C) the 
fraction of IgG is highly pure. S= serum protein 
5.2 SETTING OF PROCOAGULANT TREATMENT 
To mimic the “two-hit” theory, cells were first stimulated with LPS at 
concentration of 1 ng/ml (Raschi, 2014).  
 Then, PT was always added to the medium, since β2GpI is produced by 
monocytes and HUVECs under LPS-stimulation, while PT is produced only by 
liver cells, thus PT has to be added in each experimental condition. To facilitate 
the binding of PT to phosphatidylserine, the calcium concentration was 
adjusted to 2.5 mM (Oku, 2013). 
Lastly, to be sure that the effects seen were due to aβ2GpI IgG and/or aPS/PT 
IgG, and not to general IgG immunoglobulins, monocytes and HUVECs were 
treated with IgG fraction extracted from BD.  
5.3 EFFECT OF IgG FROM BLOOD DONORS' SERUM ON 
MONOCYTES AND HUVECs 
 
The possible effect of IgG fraction extracted from BD, was evaluated in term of 
mRNA expression after four hours of treatment. In particular, in monocytes we 
evaluated TF and IL1β mRNA expression, in HUVECs TF mRNA expression. 
In monocytes, compared to the unstimulated cells, no difference in TF up-
regulation was found between treatment with LPS alone (6.4±0.2 fold) or LPS 
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plus the IgG fraction from BD (5.2±1.4 fold) (figure 15, panel A). A similar 
scenario was found for IL1β expression (figure 15, panel B), no difference was 
observed among treatment with LPS alone or combined with IgG fraction from 
BD (respectively 8±2-fold vs 8.4±1 fold, p=0.7). 
In contrast, the treatment with BD IgG plus LPS on HUVECs determined a 
downregulation of TF mRNA expression compared to the LPS alone stimulation 
(figure 16; 18.4±5.8 fold for LPS alone, 9.6±2.4 fold for LPS plus IgG BD, 
p<0.05). 
 
Figure 15:  Monocytes obtained from five BD were stimulated as described 
below for four hours. LPS (1ng/ml) was added alone or with IgG BD fractions 
(0.5mg/ml). The bars represent the mean ± S.E. of three independent 
experiments. The expression levels of mRNA were detected by PCR real-time 
with ΔΔct method. * p< 0.05. (A) Relative TF mRNA expression levels in 




Figure 16:  HUVECs were stimulated as described below for four hours. 
LPS (1ng/ml) was added alone or with IgG BD fractions (0.5mg/ml). The bars 
represent the mean ± S.E. of three independent experiments. The expression 
levels of mRNA were detected by PCR real-time with ΔΔct method. * p< 0.05.  
Relative TF mRNA expression levels in HUVECs.  
5.4 EFFECT OF IgG FROM APS PATIENTS’ SERUM ON 
MONOCYTES 
To analyses and compare aPS/PT and aβ2GpI effect in vitro in monocytes and 
HUVECs, we stimulated cells either with the aPS/PT or the aβ2GpI IgG extract 
and with a mix 1:1 of the two extract. As shown in figure 17, in monocytes, the 
addition of IgG from APS patients significantly up-regulated the mRNA 
expression of TF compared to LPS alone. No difference was found between 
aPS/PT, aβ2GpI and the mix of the two antibodies. 
A different result was found when evaluating a proinflammatory effect in term 
of IL1β mRNA expression. In this case, while IgG aβ2GpI did not affect LPS-
induced IL1β expression, aPS/PT significantly reduced the effect of LPS on 
monocytes (figure 18). Treatment with IgG positive for both aβ2GpI and 
aPS/PT on monocytes, reflected the effects obtained separately with IgG 
positive for aβ2GpI or aPS/PT, since the negative effect of aPS/PT was partially 
reverted by aβ2GpI. 
According to these results concerning IL1β expression regulation, treatment 
with LPS in monocytes was able to switch-on the specific expression of NLRP3 
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(figure 19) and the IgG aβ2GpI further increased LPS-induced NLRP3 
expression, while aPS/PT did not, moreover, when mixed to aβ2GpI, they 
abolished the effect of aβ2GpI.    
 
 
Figure 17: Relative TF mRNA expression levels in monocytes 
Monocytes obtained from five BD were stimulated as described below for four 
hours. LPS (1ng/ml) was added alone or with IgG fractions (0.5mg/ml) 
extracted from APS patients positive for aβ2GpI, aPS/PT or both.The bars 
represent the mean ± S.E. of three independent experiments. The expression 






Figure 18: Relative IL1β mRNA expression in monocytes. 
Monocytes obtained from five BD were stimulated as described below for four 
hours. LPS (1ng/ml) was added alone or with IgG fractions (0.5mg/ml) 
extracted from APS patients positive for aβ2GpI, aPS/PT or both. The bars 
represent the mean ± S.E. of three independent experiments. The expression 
levels of mRNA were detected by PCR real-time with ΔΔct method. * p< 0.05 
 
Figure 19: Relative NLRP3 mRNA expression in monocytes. 
Monocytes obtained from five BD were stimulated as described below for four 
hours. LPS (1ng/ml) was added alone or with IgG fractions (0.5mg/ml) 
extracted from APS patients positive for aβ2GpI, aPS/PT or both. The bars 
represent the mean ± S.E. of three independent experiments. The expression 
levels of mRNA were detected by PCR real-time with ΔΔct method. 
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5.5 TF EXPRESSION IN HUVECs TREATED WITH IgG 
OBTAINED FROM APS PATIENTS’ SERUM  
HUVECs were treated with LPS alone or in combination with IgG fraction 
extract from APS patients positive for aβ2GpI or aPS/PT or both. The 
thrombotic effect was evaluated in term of TF mRNA expression. 
The addition of IgG from APS patients caused a significantly increase (p<0.001) 
of TF expression compared to LPS alone, in line with their pathogenic role in 
APS (figure 20): 18.4±5.8 fold for LPS alone, 89.5±6.8 fold for LPS plus IgG 
aβ2GpI, 86.8±2.4 fold for LPS plus IgG aPS/PT, 58.3±3.9 fold for LPS plus IgG 
positive for both.  Of note, the mix disclosed the lowest effect, as compared to 
the single antibodies. 
 
Figure 20: Relative TF mRNA expression in HUVECs. 
Cells were stimulated as described below for four hours. LPS (1ng/ml) was 
added alone or with IgG fractions (0.5mg/ml) extracted from APS patients 
positive for aβ2GpI, aPS/PT or both. The bars represent the mean ± S.E. of 
three independent experiments. The expression levels of mRNA were detected 





5.6 THE EFFECT OF IgG OBTAINED FROM APS PATIENTS’ 
SERUM ON NITRIC OXIDE (NO) PRODUCTION IN HUVECs  
NOx levels were found to be increased in cells treated respect unstimulated 
cells. In particular, as shown in figure 21, after 16 hours of treatment, NOx 
levels were significantly increased in endothelial cells treated with LPS plus IgG 
aβ2GpI or IgG aPS/PT.   No difference was found between aPS/PT, aβ2GpI and 
the mix of the two antibodies. 
 
Figure 21: Production of NOx in HUVECs. 
Cells were stimulated as described below for 16 hours. LPS (1ng/ml) was added 
alone or with IgG fractions (0.5mg/ml) extracted from APS patients positive for 
aβ2GpI, aPS/PT or both. Nox levels were measured in supernatant of treated-
cells. The bars represent the mean ± S.E. of three independent experiments. 
*p< 0.05 
5.7 SOLUBLE FACTOR RELEASED BY HUVECs AFTER 
PROCOAGULANT TREATMENT: PRELIMINARY DATA 
In order to identify soluble factor released specifically by HUVECs under 
procoagulant treatment, supernatants were analyzed by Luminex® technology, 
investigating 42 cytokines, chemokines and growth factors. Preliminary data 
are shown in table 6 and 7, where only molecules significantly upregulated 
were reported. HUVECs stimulated both by aβ2GpI IgG and aPS/PT IgG, 
compared to LPS alone, did not show different pro-inflammatory cytokine or 
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chemokine effects, while they released higher amount of the specifically 
endothelial cells activation markers, such as VCAM-1 and ICAM-1. 

















504 9 148 27 0 37 
LPS 1885 83 11151 806 5 149 
aβ2GpI 1501 60 7841 600 152 301 
aPS/PT 1885 97 10925 1094 143 290 















UNSTIMULATED 504 9 148 27 0 37 
LPS 1851 69 9749 664 7 231 
aβ2GpI 1668 69 9461 867 119 442 





5.8.1 PAF-AH PLASMATIC ACTIVITY IN PATIENTS AND CONTROLS: 
CORRELATION WITH LIPOD METABOLIC MARKERS 
PAF-AH plasmatic activity in BDs disclosed a mean value of 15.6±4 
nmol/min/ml (range 5.9 – 28.4). As expected (Maiolino, 2012), a significant 
correlation was found between PAF-AH activity and total cholesterol (r=0.25; 
p=0.032) with direct strong correlation with Low Density Lipoprotein (LDL) 
(r=0.46, p<0.0001) and significant inverse correlation with High Density 
Lipoprotein (HDL) (r= -0.45, p<0.0001). Instead, no correlation was found with 
age. 116 /167 patients undergoing aPL investigation, showed at least one 
positive aPL among LAC, aCL, aβ2GpI or aPS/PT antibodies, while 51/167 
resulted all negative. PAF-AH activity was clearly more elevated in the overall 
patients (19.8±5.5 nmol/min/ml) than in BDs (p<0.0001), but no difference 
was found between aPL positive and aPL negative patients (19.9±5.8 versus 
19.6±4.7 nmol/min/ml; figure 22). The analysis on total cholesterol shown that 
levels of cholesterol did not differ significantly between BDs and the patients. 
In particular, no difference was observed between BDs and aPL positive 
patients (188±38 mg/dl versus 198±42 mg/dl; p=0.10) and between aPL 
positive and aPL negative patients (206±52 mg/dl; p=0.47). However, LDL 
serum levels were higher in aPL negative patients than in BDs (127±42 mg/dl 
vs 104±35 mg/dl; p=0.0073) as well as in aPL positive patients (109±35 mg/dl; 
p=0.032 vs aPL negative; p=ns vs BDs). The significant correlation between 
PAF-AH activity and cholesterol, LDL and HDL serum levels persisted in aPL 
positive patients (r=0.21, p=0.041; r=0.23, p=0.024 and r= -0.31, p=0.0027 
respectively), while in aPL negative patients this correlation was evident only 




Figure 22: PAF-AH Plasmatic Activity in Patients and Controls. PAF-AH 
plasmatic activity was clearly more elevated in the all patients (19.8±5.5 
nmol/min/ml) than in BDs (p<0.0001), but no difference occurred between aPL 
positive and aPL negative patients (19.9±5.8 versus 19.6±4.7 nmol/min/ml; 
p=ns). LA positive patients disclosed higher PAF-AH than LA negative (22.1±6.4 
versus 19.5±4.1 nmol/min/ml; p=0.0032) 
5.8.2 PAF-AH PLASMATIC ACTIVITY IN PATIENTS DISCLOSING 
DISTINCT PATTERN OF aPL POSITIVITY 
Dividing aPL positive patients based on LA assay, PAF-AH activity was higher in 
LA positive patients than LA negative patients, as shown in figure 22 (22.1±6.4 
versus 19.5±4.1 nmol/min/ml; p=0.0032). Of note, total cholesterol levels did 
not differ between LA positive and LA negative patients (202±39 mg/dl versus 
201±34 mg/dl; p=ns), as well as LDL (113±39 mg/dl versus 108±26 mg/dl; 
p=ns) and HDL serum levels (60±21 mg/dl versus 63±21 mg/dl; p=ns). 
Moreover, LA positive patients disclosed higher PAF-AH than aPL negative 
patients (p=0.03), with again no difference as regard to HDL (62±24 mg/dl in 
aPL-negative; p=ns) and LDL (127±42 mg/dl in aPL-negative; p=ns). As 
illustrated in figure 23, patients presenting aβ2GpI IgG positive antibodies 
disclosed higher PAF-AH activity than patients presenting only aβ2GpI IgM 
positive antibodies (23.1±7.2 nmol/min/ml versus 20.1±5.3 nmol/min/ml; 
p=0.035), but they did not differ with regard to LDL and HDL serum levels. 
Patients who were negative for aβ2GpI IgG or IgM antibodies, but who 
showed either isolated LA or aCL or aPS/PT positive antibodies demonstrated 
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significantly lower PAF-AH activities, that appeared comparable to those 
measured in BDs (figure 17; 16.9±3.8 nmol/min/ml; p=ns versus BDs; p=0.003 
versus aβ2GpI IgM positive). Total cholesterol, LDL and HDL serum levels in the 
latter subgroup of patients did not differ from those measured in patients with 
aβ2GpI IgM positive or IgG positive antibodies.  Overall, aPS/PT IgG positive 
patients disclosed PAF-AH activity close to that of aPS/PT IgM positive patients 
(17.3±3 nmol/min/ml versus 16.1±3.9 nmol/min/ml; p=ns). Finally, patients 
disclosing aβ2GpI IgG positive antibodies together with aPS/PT IgG positive 
antibodies tended to show higher PAF-AH activity than patients disclosing only 
aβ2GpI IgG positive antibodies (23.4±7 nmol/min/ml versus 21±4.7; p=ns). 
 
Figure 23: PAF-AH plasmatic activity in patients with distinct aPL specificity. 
Patients presenting aβ2GpI IgG + antibodies disclosed higher PAF-AH plasmatic 
activity than patients presenting only aβ2GpI IgM+ antibodies (23.1±7.2 
nmol/min/ml versus 20.1±5.3 nmol/min/ml; p=0.035). Patients negative for 
aβ2GpI IgG or IgM antibodies, showing either isolated LA or aCL or aPS/PT 
positive antibodies demonstrated significantly lower PAF-AH activity (16.9±3.8 





At present, the laboratory diagnosis of APS is frequently complicated: among 
APS patients, there is a subgroup defined “seronegative” that shows clinical 
criteria but results negative for all “criteria” aPL (LA, aCL and aβ2GpI isotype 
IgG and/or IgM).  To improve APS laboratory diagnosis, it has been proposed 
several autoantibodies that are directed against other plasma proteins from 
the coagulation cascade (i.e. PS-PT complex), or interfere with the 
anticoagulant activity of A5 (Khamashta, 2016).  
aPS/PT antibodies have been proposed as potential new biomarkers for 
thrombosis and/or pregnancy morbidity in the setting of APS. The introduction 
of the aPS/PT IgM and IgG antibodies among the routinely investigated aPL 
antibodies, leads to an improvement in APS laboratory diagnostic 
performance, as shown in a recent observational study performed in our 
laboratory (Fabris, 2014). Moreover, given their elevated correlation with LA 
activity, aPS/PT could help when immunological deficits or anticoagulant 
therapy avoid a correct LA interpretation. However, their pathogenic 
mechanism is still substantially undefined.  
To date, aPS/PT antibodies are not included among “criteria” aPL. To better 
correlate the presence of aPS/PT and APS clinical manifestation, an in vitro 
study was carried out to compare the prothrombotic effect of these 
autoantibodies versus the criteria antibodies, such as the aβ2GpI. Several 
studies have already demonstrated the prothrombotic effect of aβ2GpI IgG on 
monocytes and endothelial cells (Rikarni, 2015). Indeed, aβ2GpI induce TF 
expression on these cells. On the other side, there are few information about 
the effect of aPS/PT (Oku, 2013) and no direct comparison between aβ2GpI 
and aPS/PT. 
In this study, for the first time, a pro-coagulant treatment for the 
contemporary analysis of the effect of aβ2GpI IgG and aPS/PT IgG on 
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monocytes and ECs was employed. Compared to the stimulation by the IgG 
fraction obtained by BD, either the IgG fractions by aβ2GpI positive and 
aPS/PT positive patients determined a significant activation of monocytes and 
HUVECs, showing a procoagulant phenotype. While the effect was similar in 
term of TF mRNA expression and release of specific endothelial activation 
factors (NO, ICAM, VCAM), a different effect was noticed in terms of IL-1b and 
NLRP3 expression, since aPS/PT antibodies seem to have an opposite effect 
compared to aβ2GpI. Further studies are needed to clarify these results. 
Endothelial cells are actively involved into the inflammatory process with 
specific adaptive response that includes formation of reactive oxygen species 
(ROS) with upregulation of nitric oxide (NO) production (Assis, 2002; Laurindo, 
1994).  Furthermore, endothelial dysfunction plays an important role in 
atherosclerotic disease (Pasaoglu, 2014). The upregulation of NO production in 
response to both aβ2GpI and aPS/PT antibodies indicate that they both induce 
an adaptatively response on endothelial cells.  
Several studies demonstrated that PAF-AH is a cardiovascular risk marker 
independent respect the traditional risk factors for CV. Its increased expression 
was correlated with the vulnerability of atherosclerotic plaques. Therefore, in 
order to assess the CV risk, PAF-AH dosage has been proposed to ensure a 
better stratification of at risk populations, (Corson, 2008). To date, PAF-AH has 
never been investigated in the context of APS patients, or, even less, in 
patients at risk to develop an overt APS (i.e. asymptomatic carriers of aPL 
antibodies). 
This study was conducted on patients routinely screened for APS, 
demonstrating a significant association between the presence of aPL 
antibodies (LA and aβ2GpI IgG in particular) and PAF-AH activity upregulation 
in plasma. 
Atherosclerosis is definitively recognized as a chronic inflammatory response 
due to the accumulation of lipoproteins in the walls of arteries (Libby, 2016). 
PAF-AH is manly associated with LDL and it is predominantly express in the 
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necrotic centre of atherosclerotic plaques and in the macrophage-rich areas 
releasing pro-inflammatory mediators, such as lysophospholipids and oxidized 
fatty acids (Rosenson, 2012). 
In addition to the presence of LA, several different targets of aPL could be 
determined by many analytical methods, with frequent discordant results, 
that could make the laboratory diagnosis of APS extremely complicated. The 
main role of the aβ2GpI antibodies, especially those specifically targeting 
domain I (Giannakopoulos, 2013), is widely accepted and present results seem 
to further confirm their importance with regard to CV risk stratification, since 
PAF-AH appeared particularly elevated in aβ2GpI positive patients and more so 
in those displaying LA activity and carrying the IgG isotype. This particular 
association may be explained by the fact that IgG aβ2GpI antibodies are able 
to recognize the stable complex between oxLDL and β2GpI, thus facilitating 
macrophage-derived foam cell formation in patients with APS (Zhang, 2014). 
The immune-pathological mechanisms sustained by oxLDL/β2GpI complexes 
are not yet fully understood, but TLR4 was recently shown to be involved 
(Zhang, 2014). TLR4 could be the key player linking PAF-AH up-regulation to 
aβ2GpI IgG antibodies in APS, as evidenced by a mouse model of preterm 
delivery which demonstrated that PAF effects and signalling depend upon 
TLR4 stimulation (Agrawal, 2014).  
Lp-PLA2 activity proved to be markedly reduced in vivo when the enzyme is 
bound to HDL (Rosenson, 2012), and this is in line with our observation that 
aβ2GpI IgG+ patients disclosed higher PAF-AH and lesser HDL than BDs. This is 
not true for other subgroups of patients, such as aPL-negative patients or 
those presenting only isolated LAC or aCL or aPS/PT antibodies. Compared to 
these patients, PAF-AH plasmatic activity up-regulation in aβ2GpI IgG+ cases 
appeared to be at least partially disconnected from the lipoprotein levels and 
specifically linked to the presence of such aPL antibodies.  
Therefore, PAF-AH up-regulation arose as a specific thrombotic risk marker in 
patients carrying aβ2GpI antibodies and is not generally associated with other 
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aPL antibodies possibly implicated in APS manifestations, but further studies 
are needed to confirm this observation.  
Unfortunately, in two large randomized clinical trials, an inhibitor of PAF-AH 
(darapladib) (O’Donoghue, 2014; Wallentin, 2016) failed to reduce the risk of 
major coronary events as compared to placebo. In addition, it was associated 
with significantly higher rates of drug discontinuation and adverse effects. 
These results suggested that PAF-AH may be a biomarker of vascular 
inflammation, rather than a causal pathway of CV diseases (Wallentin, 2016). 
Therefore, high PAF-AH activity could reflect a response to pro-inflammatory 
stress characteristic both of atherosclerosis and APS (Marsthe, 2014). 
The leading cause of death in primary and secondary APS patients are 
cardiovascular events due to accelerated atherosclerosis, which often 
progresses more rapidly, compared with the general population (Silva, 2014). 
Some key pro-inflammatory proteins correlate with APS clinical manifestations 
(Becarevic, 2016) and common radiological markers of 
subclinical atherosclerosis and CV risk were often reported in such patients 
(Ambrosino, 2014). However, to date, besides the presence of aPL itself, no 
serological biomarkers specifically associated with aPL-related pathogenic 
mechanisms have been identified as useful to improve the classification of CV 
risk in aPL+ patients with and without overt APS clinical manifestations.  
In this scenario, present findings on PAF-AH assume a relevant place, possibly 
representing a reliable and affordable biomarker useful to identify patients at 
higher risk in which to take a more cautious therapeutic attitude in the follow-
up. 
Moreover, studying PAF-AH metabolic pathway may help to better explain the 
pathogenesis of APS and to improve management and interpretation of aPL-
related issues, from the analytical result, to the final therapeutic decision.  
Even if we and others recently demonstrated an important role of aPS/PT 
antibodies in the laboratory diagnosis of APS (Fabris, 2014; Amengual, 2016), 
the therapeutic management of patients characterized by the presence of 
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isolated aPS/PT remains an open issue. Patients with isolated aPS/PT 
antibodies disclosed lower (BDs-like) PAF-AH as compared to patients with 
positive aβ2GpI antibodies. Nevertheless, aPS/PT antibodies, may exert their 
distinct pathogenic role through pathways in which PAF-AH is not involved, as 
shown previously as regard to IL1b and NLRP3 expression on monocytes 





The introduction of aPS/PT antibodies in the diagnostic process of APS is 
highly recommended, since they disclosed diagnostic laboratory performances 
at least equal to the aCL and aβ2GpI antibodies and a high correlation with LA 
activity, such that they can be a viable alternative. 
Data obtained by our in vitro study, even if preliminary, confirmed that aPS/PT 
exert similar pro-thrombotic effects on monocytes and HUVECs as compared 
to the aβ2GpI antibodies. The different effect of aβ2GpI and aPS/PT on 
expression of IL1β and NLRP3, and the different impact on PAF-AH production, 
may suggest that these classes of antibodies, while disclosing similar pro-
thrombotic effects, probably activate different metabolic pathways. Further 
studies are needed to better clarify these issues. 
Anyway, the prognostic information conveyed by plasmatic PAF-AH activity in 
patients with positive aPL antibodies appeared to be independent to that of 
common lipid metabolism markers (i.e. LDL), as previously reported by other 
authors in the context of patients with major coronary events (Maiolino, 2012) 
and, based on present results, PAF-AH plasmatic activity may represent a new 
prognostic biomarker also in the context of aPL antibodies, to identify patients 
at major risk and favouring more tailored therapeutic interventions. Further 
prospective studies on selected patients are ongoing.  
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